ALKBH5 and non-small cell lung carcinoma: Several studies on lung cancer have shown that FTO plays a cancer-promoting role through m6A modification in lung squamous cell carcinoma and adenocarcinoma [37–39], whereas ALKBH5 inhibits NSCLC tumorigenesis by reducing YTHDFs-mediated YAP expression [40].